Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -98.4% | -26.5% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -321.7% | -703.7% | -2,019.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -209,712.4% | -6,478.3% | -61,829.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -368,036.5% | -6,050.5% | -62,377.5% |
| EPS Diluted | -0.1 | -0.21 | -0.21 | -3.01 |
| % Growth | 52.4% | 0% | 93% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |